Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-11-20
2007-11-20
Zara, Jane (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091310, C435S455000, C536S023100, C536S024500
Reexamination Certificate
active
10637443
ABSTRACT:
This disclosure provides TRT antisense oligonucleotides, methods of detecting TRT, methods of diagnosing telomerase-related conditions, methods of diagnosing and providing a prognosis for cancer, and methods of treating telomerase-related conditions, including cancer.
REFERENCES:
patent: 5583016 (1996-12-01), Villeponteau
patent: 5639613 (1997-06-01), Shay
patent: 5643890 (1997-07-01), Iversen et al.
patent: 5767102 (1998-06-01), Draper et al.
patent: 5968506 (1999-10-01), Weinrich et al.
patent: 6040181 (2000-03-01), Reed
patent: 6093809 (2000-07-01), Cech et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6309867 (2001-10-01), Cech et al.
patent: 6331399 (2001-12-01), Monia et al.
patent: 6337200 (2002-01-01), Morin
patent: 6383808 (2002-05-01), Monia et al.
patent: 6440735 (2002-08-01), Gaeta
patent: 6444650 (2002-09-01), Cech et al.
patent: 6475789 (2002-11-01), Cech et al.
patent: 6492171 (2002-12-01), Monia et al.
patent: 6548298 (2003-04-01), Villeponteau et al.
patent: 6607720 (2003-08-01), Xiao et al.
patent: 6608188 (2003-08-01), Tsuchiya et al.
patent: 6610839 (2003-08-01), Morin et al.
patent: 6617110 (2003-09-01), Cech et al.
patent: 6627619 (2003-09-01), Cech et al.
patent: 6767719 (2004-07-01), Morin et al.
patent: 6777203 (2004-08-01), Morin et al.
patent: 6808880 (2004-10-01), Cech et al.
patent: 6921664 (2005-07-01), Cech et al.
patent: 6927285 (2005-08-01), Cech et al.
patent: 7005262 (2006-02-01), Cech et al.
patent: 7056513 (2006-06-01), Cech et al.
patent: 7091021 (2006-08-01), Morin
patent: 7195911 (2007-03-01), Cech et al.
patent: 2003/0059787 (2003-03-01), Cech et al.
Agrawal S. Antisense oligonucleotides: toward clinical trials, TIBTECH, 1996, 14, 376-387.
Branch A. D., A good antisense molecule is hard to find, TIBS, 1998, 23, 45-50.
Braasch D. A. et al. Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression, Biochemistry, 2002, 41, 4503-4509.
Gewirtz A.M. et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise, Proc. Natl. Acad. Sci. USA, 1996, 93, 3161-3163.
Tamm I. et al., Antisens therapy in oncology: n w hope for an old Idea? The Lancet, 2001, 358, 489-497.
Hahn W. C. Inhibition of telomerase limits the growth of human cancer cells, Nature Medicine, 1999, 5, 1164-1170.
Asai A et al, A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer Agent, Cancer Res 63:3931 (Jul. 2003).
Folini M et al, Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes, Curr Med Chem 2:605 (2002).
Hao ZM et al, Design of a Ribozyme Targeting Human Telomerase Reverse Transcriptase and Clonig of it's Gene, World J Gastroent 9(1):104 (Jan. 2003).
Komata T et al, Telomerase as Therapeutic Target for Malignant Gliomas, Oncogene 21:656 (2002).
Pruzan R et al, Allosteric Inhibitors of Telomerase: Oligonucleotide N3′→P5′ Phosphoramidates, Nucleic Acids Res 30(2):559 (2002).
Saretzki G et al, Ribozyme-Mediated Telomerase Inhibition Induces Immediate Cell Loss but not Telomere Shortening in Ovarian Cancer Cells, Cancer Gene Therapy 8(10):827 (2001).
Schindler A et al, Human Telomerase Reverse Transcriptase Antisense Treatment Downregulates the Viability of Prostate Cancer Cells in Vitro, Intl J Oncology 19:25 (2001).
Shay JW et al, Telomerase: A Target for Cancer Therapeutics, Cancer Cell 2:257 (Oct. 2002).
Teng L et al, Antisense hTERT Inhibits Thyroid Cancer Cell Growth, J Clin Endocrin Metab 88(3):1362 (2003).
Yokoyama Y et al, The 5′-End of hTERT mRNA is a Good Target for Hammerhead Ribozyme to Suppress Telomerase Activity, Biochem Biophys Res Comm 273:316 (2000).
Yuan Z et al, Inhibition of Telomerase Activity with hTERT Antisense Increases the Effect of CDDP-Induced Apoptosis in Myeloid Leukemia, Hemato J 3:201 (2002).
Harrington, Lea, et al. (1997) “A Mammalian Telomerase-Associated Protein”,Science275:973-977.
Langford, Lauren A., et al. (1997) “Telomerase Activity in Ordinary Meningiomas Predicts Poor Outcome”,Human Pathology28(4):416-420.
Nakamura, Toru, M., et al. (1997) “Telomerase Catalytic Subunit Homologs from Fission Yeast and Human”,Science. 277:955-959.
Harrington, Lea, et al. (1995) “Gel Shift and UV Cross-linking Analysis ofTetrahymenaTelomerase”,The Journal of Biological Chemistry, 270(15):8893-8901.
Collins, Kathleen, et al. (1995) “Purification of Tetrahymena Telomerase and Cloning of Genes Encoding the Two Protein COmponents of the Enzyme”,Cell, 81:677-686.
Greider, Carol W. (1998) Telomerase and senescence: The history, experiment, the future,Current Biology, 8(5):R178-R181.
Kilian, Andrzej, et al. (1997) “Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing paterns in different cell types”,Human Molecular Genetics, 6(12):2011-2019.
Meyerson, Matthew, et al. (1997) “hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization”,Cell90:785-795.
Morin, G.B. (1997) “The Implications of Telomerase Biochemistry for Human Disease”,European Journal of Cancer, 33(5):750-760.
Gura, Science vol. 270, pp. 575-577, 1995.
EST, Accession No. AA281296, NCBI database, 1997.
EST, Accession No. AA311750, NCBI database, 1997.
EST, Accession No. AA299878, NCBI database, 1997.
Adams M. et al. Initial Assessment of Human Gene Diversity and Expression Patterns Based upon 83 Million Nucleotides of cDNA Sequence. Nature, 377, supp. 28 Sep. 1995, 3-174.
Lanfranchi G. et al. Identification of 4370 Expressed Sequence Tags from a 3′-End-Specific cDNA library of Human Skeletal Muscle by DNA Sequencing and Filter Hybridization, Genome Res., 6, 1996, 35-42.
Bonaldo M. et al. Normalization and Subtraction: Two Approaches to Facilitate Gene Discovery, Genome Res. 6, 1996, 791-806.
Declaration under 37 CFR § 1.56 listing other issued patents and pending applications for telomerase reverse transcriptase.
U.S. Appl. No. 09/721,506, Pending Claims, Cech, T. R., et al., Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs Having Telomerase Activity.
U.S. Appl. No. 10/044,692, Pending Claims, Cech, T. R., et al., Nucleic Acid Vaccine for Eliciting an Immune Response Against Telomerase Reverse Transcriptase.
U.S. Appl. No. 10/054,611, Allowed Claims, Cech, T. R., et al., Methods for Detecting Nucleic Acids Encoding Human Telomerase Reverse Transcriptase.
Genta Inc. press release May 16, 2005.
Genta Inc. press release Sep. 19, 2005.
Geron Corporation press release Jul. 27, 2005.
Information download from ISIS Pharmaceuticals website on Nov. 8, 2005.
OncoGeneX press release Sep. 7, 2005.
Aboul-Fabl, T., Antisense Oligonucleotides: The State of the Art, Current Medicinal Chemistry 12:2193 (2005).
Asai, A., et al., A Novel Telomerase Template Antagonist (GRN 163) as a Potential Anticancer Agent, Cancer Reserach, 63:3931 (Jul. 2003).
Banerjee D., Technology evaluation: G-3139, Curr Opin Mol Ther. 1(3):404 (Jun. 1999) (Abstract).
Chi K.N., et al., A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2′-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients with Localized Prostate Cancer, J. Natl. Cancer Inst. 97(17):1287 (Sep. 2005).
Du, Q., et al., Antitumor Mechanism of Antisense Cantide Targeting Human Telomerase Reverse Transcriptase, World J. Gastroenterol 9(9):2030 (2003).
Folini, M., et al., Antisense Oligonucleotide-mediated inhibition of hTERT, but not hTERC, Induces Rapid Cell Growth Decline and Apoptosis in the Absence of Telomere Shortening in Human Prostate Cancer Cells, European J. of Cancer 41:624 (2005).
Fu, X., et al., Combination of Telomerase Antisense Oligonuleotides Simutaneously Targeting hTR and hTERT Produces Synergism of Inhibition of Telomerase Activity and Growth in Human Colon Cancer Cell Line, World J. Gastroenterol 11(6):785 (2005).
Galderisi, U., et al., Antisense Oligonucleotides as Therapeutic Agents, J. of Cellular Phys
Andrews William H.
Cech Thomas R.
Chapman Karen B.
Harley Calvin B.
Lingner Joachim
Geron Corporation
The Regents of the University of Colorado
Zara Jane
LandOfFree
Identifying and testing antisense oligonucleotides that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identifying and testing antisense oligonucleotides that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identifying and testing antisense oligonucleotides that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3880199